President Trump launched TrumpRx, a government-backed platform aimed at lowering out-of-pocket drug costs for Americans.

Despite initial concerns about pricing pressure, major pharmaceutical stocks rallied on February 6, signaling investors don’t see TrumpRx as a near-term threat to earnings. The platform targets cash-paying and uninsured consumers, leaving insurance and institutional revenue untouched.

The voluntary, trade-linked nature of TrumpRx has markets treating it as a contained policy move, supporting broader risk sentiment across equities and even crypto.